The Phase I/II trial with Remygen® for the regeneration of insulin-producing cells is recruiting patients

Recruitment of patients is ongoing to the first part of the clinical Phase I/II trial ReGenerate-1, with Diamyd Medical's orally administered GABA-based investigational drug Remygen®. The trial is conducted at Uppsala University Hospital and is directed at patients aged 18-50 years who have type 1 diabetes since more than five years and with low or non-existent insulin production."ReGenerate-1 is an exciting trial in type 1 diabetes," says Per-Ola Carlsson, Professor at Uppsala University and Uppsala University Hospital, Sponsor of the trial. "The trial gives us a unique opportunity to